Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"Circulating tumour DNA"”.
-
Circulating Tumour DNA in Localised Urological Cancers
… delaying definitive treatment. Cell-free mutant DNA (mutDNA) analysis represents an opportunity for non-invasive monitoring of cancer through tumour genome analysis. MutDNA derived from plasma can monitor tumour burden. There is emerging evidence that mutDNA can identify mutations from multiple …
-
Circulating tumour DNA: A non-invasive biomarker for melanoma
… The detection and analysis of mutant specific circulating tumour DNA (ctDNA) is an emerging tool for detection of residual disease and for prognosis and monitoring of different cancers (Bettegowda et al., 2014; Dawson et al., 2013; Gray et al., 2015; Spindler et al., 2012). There is however, …
-
Investigating the Mechanisms and Kinetics of Circulating Tumour DNA Release to Improve its Clinical Utility
… and enable personalized treatment regimens. Circulating tumour DNA (ctDNA) has sparked tremendous interest in the last decade as a non-invasive method to monitor dynamic changes in treatment response. However, the mechanisms that dictate ctDNA release kinetics have not been thoroughly …
-
Molecular characterization of methylated circulating tumour DNA biomarkers and their detection with low-cost biosensor
… of cancers. Recently, cell-free methylated DNA immunoprecipitation (cfMeDIP) method was used to distinguish localized from advanced prostate cancers with high sensitivity. The challenge in prostate cancers is that the methylation levels are notoriously heterogeneous, which may lead to …
-
Exploration of cell-free DNA’s biological properties for better understanding and improved circulating tumour DNA detection
… that can be used for cancer profiling. Cell-free DNA (cfDNA) are fragmented DNA shed into circulation from various types of cells. The cfDNA derived from cancer cells, circulating tumour DNA (ctDNA), forms a subset of cfDNA. It can be challenging to detect ctDNA as it often constitutes only a …
-
Detection of trace levels of circulating tumour DNA in early stage non-small cell lung cancer
Liquid biopsies, using analytes such as circulating tumour DNA (ctDNA), can detect and quantify cancer in a minimally invasive way and can provide information on tumour heterogeneity. Current limitations in the liquid biopsy field are centred around the general sensitivity of the present assays and …
-
Latent feature models and non-invasive clonal reconstruction
Intratumoural heterogeneity complicates the molecular interpretation of biopsies, as multiple distinct tumour genomes are sampled and analysed at once. Ignoring the presence of these populations can lead to erroneous conclusions, and so a correct analysis must account for the clonal structure of …
-
Approaches to developing clinically useful Bayesian risk prediction models
… usefulness of including information about circulating tumour DNA (ctDNA) when predicting response to treatment in metastatic breast cancer. ctDNA has been proposed as a promising approach to assess response to treatment. We show that incorporating trajectories of circulating tumour DNA …
-
Cellular and molecular mechanisms of response to, and recurrence following, breast radiotherapy
… surgery and radiotherapy. Ipsilateral breast tumour recurrences following breast conserving treatment have long been noted to predominantly occur in or close to the tumour bed from which the index cancer was removed with a smaller number arising in other quadrants of the breast. A widely held …
-
Investigating the utility of blood borne oncological biomarkers in solid tumours: glioma and melanoma
… into the potential utility of these circulating biomarkers as analytic test measures complementing radiological imaging have been occasioned by the invasive nature of malignant tumour tissue biopsy, the need for serial evaluation of tumour burden during therapy, and the need for …
-
The application of genomic technologies to cancer and companion diagnostics.
… (study of RNAs) and methylome (study of DNA methylation). As cancer is a disease of the genome the rapid advances in genomic technology, specifically microarrays and next generation sequencing, are creating a wave of change in our understanding of its molecular pathology. Molecular …
-
Dynamics and utility of cell-free DNA release following radiotherapy in prostate cancer and non-small cell lung cancer
… The tissue-of-origin of plasma cell-free DNA (cfDNA) can be determined by methylation analysis and circulating tumour DNA identified by next-generation sequencing (NGS). To evaluate the dynamics of cfDNA during radical radiotherapy, total cfDNA was quantified in patients undergoing …
-
Improving earlier non-invasive diagnosis of high-grade serous ovarian cancer
… as a first step in developing a diagnostic circulating tumour DNA (ctDNA) biomarker for high grade serous ovarian cancer (HGSOC), was to investigate low-cost high-throughput next generation sequencing assays in plasma samples collected from women with newly diagnosed OC. The secondary aim …
-
The clonal architecture and tumour microenvironment of breast cancers are shaped by neoadjuvant chemotherapy
… of response, though little is known on how tumours and their microenvironments are modulated by neoadjuvant chemotherapy. The thesis aims at molecularly characterising tumour changes during neoadjuvant chemotherapy in a cohort of 168 patients. Serial tumour samples at diagnosis, and, when …
-
Exploring the effect of peri-operative inflammation on systemic and local breast cancer biomarkers
… of breast cancer inflammation and influence circulating tumour DNA (ctDNA)release which may predict clinical and oncological outcomes. Aims 1. To understand the relationship between peri-operative systemic inflammation and breast tumour characteristics, surgical intervention and 30-day …
-
Biomarkers of Genome Instability and Disease Progression in Ovarian Cancer
… is highly prevalent in HGSOC and displays marked tumour heterogeneity. We report that CA is associated with increased CIN and, importantly, genome subclonality. Consequently, we highlight CA and associated vulnerabilities/survival mechanisms as promising targets for novel treatment strategies in …
-
Surface Plasmon Resonance Imaging Biosensors for Cancer Diagnosis: Detection of Circulating Tumor DNA
… to ensure the hybridization reaction of PNA-DNA complexes. The spatially controlled immobilization of PNA probes has been obtained by injecting PNA wild-type and PNA mutated solutions into a microfluidic system coupled to SPR sensor chip. The extremely low concentration of genomic DNA …
-
Imaging Metabolic Signatures in High Grade Serous Ovarian Cancer
… cancer and has demonstrated inter and intra-tumoural metabolic heterogeneity, where metabolic differences were observed between patients and between different tumour deposits within the same patient. Here I compared the use of <sup>13</sup>C magnetic resonance spectroscopic imaging (MRSI) of …
-
Characterising DNA methylation in tissue and liquid samples from patients with renal tumours
… diagnoses, including benign and malignant tumours, the most common of which is clear cell RCC (ccRCC). Current methods are unable to confidently distinguish pathological subtypes of SRMs, meaning patients with benign tumours are undergoing unnecessary invasive surgery. In addition, there …
-
Assessment of the clinical validity of ctDNA Analysis for melanoma management
… of patient disease status are urgently required. Circulating tumour DNA (ctDNA) analysis has emerged as a potential “liquid biopsy” for melanoma. Plasma-derived ctDNA are short DNA fragments released into the bloodstream by apoptotic tumour cells. Studies have shown that ctDNA levels in blood …
Page 1 of 2